Amendments to the Claims:

1. (Currently Amended) A method for ~~preventing or for~~ treating chronic pain comprising administering to a patient in need of treatment an effective amount of a synergistic combination of a NK_1 receptor antagonist and a GABA analog.

2. (Original) A method of Claim 1 wherein the ratio of the GABA analog relative to the NK_1 receptor antagonist is from 50:1 to 1:1 expressed as parts by weight.

3. (Original) A method according to Claim 1 wherein the ratio of the GABA analog relative to the NK_1 receptor antagonist is 20:1 expressed as parts by weight

4. (Original) A method according to Claim 1 wherein the NK_1 receptor antagonist is [2-(1*H*-indol-yl)-1-methyl-l-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethylester [R-(R*,S*)].

5. (Original) A method according to Claim 1 wherein the GABA analog is gabapentin.

6. (Original) A method according to Claim 1 wherein the GABA analog is pregabalin.

7. (Original) A method according to Claim 1 employing [2-(l*H*-indol-3-yl)- l-methyl-l-(1-phenyl-ethylcarbamoyl)-ethyl]-carhamic acid benzofuran-2-ylmethyl ester[R-(R*,S*)] and gabapentin.

8. (Original) A method according to Claim 1 employing [2-(l*H*-indol-3-yl)-l-methyl-l-(1 -phenyl-ethylcarhamoyl)-ethyl]-carbamic acid benzofuran-2-yhnethyl ester[R-(R*,S*)] and pregabalin.

9. (Original) A method according to Claim 1 wherein the condition treated is selected from causalgia, neuropathic pain, diabetic neuropathy, post-surgery or traumatic neuropathy, postherpetic neuralgia, peripheral neuropathy, entrapment neuropathy,

phantom limb and stump pain, neuropathy caused by alcohol abuse, HIV infection, multiple sclerosis, hypothyroidism or anticancer chemotherapy.

10. (Original) A pharmaceutical composition comprising synergistic effective amounts of a NK_1 receptor antagonist and a GABA analog.

11. (Original) A composition of Claim 10 wherein the ratio of the GABA analog relative to the NK_1 receptor antagonist is from 50:1 to 1:1 expressed as parts by weight.

12. (Original) A composition of Claim 10 wherein the ratio of the GABA analog relative to the NK_1 receptor antagonist is 20:1 expressed as parts by weight.

13. (Original) A composition of Claim 10 wherein the NK_1 receptor antagonist is [2-(1*H*-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)].

14. (Original) A composition of Claim 10 wherein the GABA analog is gabapentin.

15. (Original) A composition of Claim 10 wherein the GABA analog is pregabalin.

16. (Original) A composition of Claim 10 employing [2-(1*H*-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)] and gabapentin.

17. (Original) A composition of Claim 1 employing [2-(1*H*-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)] and pregabalin.

18. (Cancel) ~~The use of a composition comprising synergistic effective amounts of a NK_1 receptor antagonist and a GABA analog, or pharmaceutically acceptable salts thereof, for the preparation of a medicament useful for preventing or treating chronic pain.~~